Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82

Susana S. Najera(Frederick National Laboratory for Cancer Research), Jordan L. Meier(National Cancer Institute)
Molecular Cancer Therapeutics
October 12, 2024
Cited by 8


Related Papers